CVS Health Corporation (NYSE:CVS) is one of the most undervalued blue chip stocks to buy now. Bernstein Raises PT on CVS Health (CVS) to $91, Reiterates ‘Market Perform’ Rating On January 6, 2026, Bernstein increased its price target on CVS Health Corporation (NYSE:CVS) from $87 to $91, while reiterating a ‘Market Perform’ rating. The investment firm expects a broader inflection in the government-managed care organization (MCO) sector beginning in 2026. The firm projects short-term earnings recovery, dri ...

CVS Health Corporation (NYSE:CVS) is included among the 20 Best Performing Dividend Stocks in 2025. JPMorgan Names CVS a Top Pick as Turnaround Gains Traction The stock dropped 43% in 2024, then swung the other way with an 80.5% gain this year. Even after that run, Wall Street still sees room to move. The average analyst price target points to another 19% upside.Earlier in December, JPMorgan named CVS Health Corporation (NYSE:CVS) as a top pick in health care services. “We remain positive on CVS post-Inv ...